AzTrials
AzTrials

Idiopathic ScoliosisNCT07873554

Real-World Effectiveness of Conservative Treatment in Idiopathic Scoliosis

An observational study of Idiopathic Scoliosis and Adolescent Idiopathic Scoliosis (AIS), run by Istituto Scientifico Italiano Colonna Vertebrale at 1 site in Italy.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

This retrospective observational study aims to assess the real-world effectiveness of conservative treatment (bracing and specific exercises) in patients with idiopathic scoliosis treated with an Evidence-Based Personalised Approach (EBPA). Read more about this study

Who is it for?
Ages Up to 18 years
What is being tested?
Brace and Specific exercises (SEAS)
Type of treatment
Medical device
How many people
30,000 participants
Where
1 siteItaly
Study dates
2 Oct 2026to 2 Oct 2029
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Study population: Patients with infantile, juvenile or adolescent idiopathic scoliosis treated conservatively at ISICO (Italian Scientific Spine Institute) and recorded in the institutional clinical database between March 2003 and the date of data extraction (about 30,000 patients).

Who may be able to join

  • Diagnosis of idiopathic scoliosis (infantile, juvenile or adolescent)
  • Initial Cobb angle between 10° and 60°
  • Radiographic and clinical data available at start of treatment and at its conclusion (skeletal maturity or end of growth)
  • Consent to the processing of personal data for research purposes

Who cannot join

  • Secondary scoliosis (neuromuscular, syndromic, congenital)
  • Previous spinal surgery, or immediate surgical indication at first visit (patients who refused the surgical indication remain eligible)
  • Missing minimum data required to apply the prognostic models Contacts/Locations

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • ISICO - Italian Scientific Spine Institute

    Milan

Other trials in Italy

About this study

Official title: Real-World Effectiveness and Validation of Prognostic Models in the Conservative Treatment of Spinal Deformities: a Retrospective Observational Study in a Cohort of 30,000 Patients

This retrospective observational study aims to assess the real-world effectiveness of conservative treatment (bracing and specific exercises) in patients with idiopathic scoliosis treated with an Evidence-Based Personalised Approach (EBPA). Clinical records of about 30,000 patients collected in the institutional database of ISICO (Italian Scientific Spine Institute, Milan, Italy) since 2003 will be analysed. For each patient, the expected natural history (risk of progression without treatment) will be estimated with two validated prognostic models, IS-GROWTH and BrAIST-Calc. The outcome observed at skeletal maturity will be compared with the predicted risk to measure treatment effectiveness in preventing the 30°, 45° and 50° Cobb thresholds. Secondary aims include subgroup analyses by age at onset (infantile, juvenile, adolescent), validation of the prognostic models in the Italian population, over- and under-treatment rates, drop-outs and compliance, quality of life of patients and parents, and comparison between treatment tools.

Read the detailed description

Background. Idiopathic scoliosis is a three-dimensional deformity of the spine affecting 2-3% of the paediatric population, mainly during adolescence (adolescent idiopathic scoliosis, AIS). If not adequately treated during pubertal growth, the curve may progress beyond critical thresholds: 30° Cobb, below which the risk of chronic back pain and progression in adulthood is very low, and 45-50° Cobb, the surgical threshold.

The current evidence on bracing in AIS is based on the BrAIST randomised controlled trial, which showed that bracing prevents surgery. However, RCTs have intrinsic limits of generalisability: (1) strict inclusion criteria, since BrAIST included only about 2% of the real clinical population; (2) a single standardised treatment, while in clinical practice treatment is personalised according to patient response and shared decision making (EBPA); (3) a focus on AIS, leaving infantile and juvenile forms poorly studied.

This study will use validated prognostic models (IS-GROWTH and BrAIST-Calc) to build an individualised control population based on each patient's predicted risk of progression without treatment. Comparing the outcome observed at skeletal maturity with the predicted risk allows the effectiveness of treatment to be measured in a real-world setting on an unprecedented scale.

Design. Retrospective, observational, non-pharmacological, non-profit study based on data collected during routine clinical practice in the ISICO institutional clinical database, active since 2003. The study is a pragmatic benchmarking of clinical practice.

Data collected. Parameters recorded every 4-6 months during treatment will be extracted: radiographic data (Cobb angle, Risser stage, sagittal parameters: kyphosis and lordosis); clinical data (angle of trunk rotation, ATR; Trunk Aesthetic Clinical Evaluation, TRACE; weight; height); quality-of-life questionnaires (SRS-22, ISYQOL, SCaRES); treatment data (brace type: Sibilla, Lapadula, Sforzesco, PASB; prescribed and actual brace wear time, self-reported or measured with thermal sensors; Scientific Exercises Approach to Scoliosis, SEAS).

Definition of success. (1) Stability or improvement of the Cobb angle (change < 5° or reduction ≥ 5°); (2) prevention of surgery, i.e. not reaching 45° (BrAIST-Calc) and 50° Cobb (IS-GROWTH); (3) low-risk target, i.e. end of growth with a curve < 30° Cobb.

Statistical analysis. Analyses will be performed mainly with R: descriptive statistics (mean and standard deviation, or median and percentiles; frequencies with 95% confidence intervals); standardised incidence ratio (SIR) of observed versus expected cases according to natural history models, with 95% confidence intervals and Poisson statistics; relative risk (RR) and number needed to treat (NNT); intention-to-treat analysis, with drop-outs considered treatment failures; per-protocol analysis. Sample size is not predetermined: the whole eligible population will be analysed to maximise statistical power in subgroup analyses.

Ethics and data protection. The study is conducted in accordance with the Declaration of Helsinki. As a retrospective analysis of routinely collected data, it involves no additional risk for participants. Given the objective impossibility of contacting all patients, a waiver of informed consent is requested from the Ethics Committee, in accordance with GDPR articles 6, 9(2)(j) and 89, article 110 of the Italian Privacy Code and the Italian Data Protection Authority provision of 9 March 2023. A Data Protection Impact Assessment (DPIA) will be performed. Data will be pseudonymised and analysed only in aggregate form.

Being tested
Brace, Specific exercises (SEAS)
Keywords
bracing, Conservative Treatment, Evidence-Based Personalised Approach

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • BraceDevice

    Conservative treatment with a spinal brace (Sibilla, Lapadula, Sforzesco or PASB) prescribed during routine clinical practice, with personalised wear time. Prescribed and actual wear time (self-reported or measured with thermal sensors) are recorded. No intervention is assigned by the study.

  • Specific exercises (SEAS)Other

    Physiotherapeutic Scoliosis-Specific Exercises according to the Scientific Exercises Approach to Scoliosis (SEAS) protocol, prescribed during routine clinical practice. No intervention is assigned by the study.

Study groups in NCT07873554
Study groupRoleWhat they receive
Infantile idiopathic scoliosisPatients with idiopathic scoliosis with onset at 0-3 years, treated conservatively
Receives: Device: Brace; Other: Specific exercises (SEAS)
Juvenile idiopathic scoliosisPatients with idiopathic scoliosis with onset at 4-9 years, treated conservatively
Receives: Device: Brace; Other: Specific exercises (SEAS)
Adolescent idiopathic scoliosisPatients with idiopathic scoliosis with onset at 10-18 years, treated conservatively
Receives: Device: Brace; Other: Specific exercises (SEAS)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of patients exceeding clinical severity thresholds (30°, 45° and 50° Cobb) at skeletal maturity, compared with predicted natural history

    Observed proportion of patients reaching 30°, 45° and 50° Cobb at skeletal maturity, compared with the proportion expected from the IS-GROWTH (50°) and BrAIST-Calc (45°) prognostic models. Effectiveness is expressed as standardised incidence ratio (SIR) with 95% CI, relative risk (RR) and number needed to treat (NNT).

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

Secondary outcomes (10)
  1. Treatment effectiveness by age at onset

    Percentage of patients reaching 30°, 45° and 50° Cobb at skeletal maturity, stratified by infantile (0-3 years), juvenile (4-9 years) and adolescent (10-18 years) idiopathic scoliosis.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  2. Predictive accuracy of IS-GROWTH and BrAIST-Calc

    Discrimination of each prognostic model in the Italian population, expressed as area under the ROC curve (AUC) for predicting curve progression to 50° (IS-GROWTH) and 45° Cobb (BrAIST-Calc).

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  3. Rate of over-treatment and under-treatment

    Proportion of patients treated despite low predicted risk and of patients not adequately treated despite high predicted risk.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  4. Cobb angle stability or improvement

    Proportion of patients with stable (change < 5°) or improved (reduction ≥ 5°) Cobb angle at end of treatment compared with baseline.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  5. Drop-out rate and reasons

    Percentage of patients abandoning treatment before skeletal maturity; reasons for drop-out are reported descriptively.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  6. Brace compliance

    Actual brace wear time in hours per day (self-reported or measured with thermal sensors), compared with prescribed wear time.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  7. Determinants of treatment outcome

    Odds ratios of baseline clinical and treatment variables associated with treatment success, estimated with multivariable predictive models.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  8. Patient quality of life

    Change from baseline in Scoliosis Research Society-22 (SRS-22) total score. Score range 1-5; higher scores indicate better quality of life. Change from baseline in Italian Spine Youth Quality of Life (ISYQOL) score. Score range [0-100]; higher scores indicate better quality of life.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  9. Parent-reported quality of life

    Change from baseline in Scoliosis Caregiver Response and Emotional Scale (SCaRES) score. Score range [0-100]; higher scores indicate [better/worse] outcome.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

  10. Comparison between treatment tools

    Outcome of comparable patient groups treated with different braces (Sibilla, Lapadula, Sforzesco, PASB) and exercises.

    Measured: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted14 Oct 2026
  2. Study start2 Oct 2026
  3. Primary completion2 Oct 2028 (estimated)
  4. Study completion2 Oct 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
30,000 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07873554
Sponsor's protocol ID
ID 6947
Status last verified
Oct 2026
First submitted
2 Oct 2026
Last updated
14 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Idiopathic Scoliosis and Adolescent Idiopathic Scoliosis (AIS), run by Istituto Scientifico Italiano Colonna Vertebrale at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 14 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients exceeding clinical severity thresholds (30°, 45° and 50° Cobb) at skeletal maturity, compared with predicted natural history (time frame: From start of conservative treatment to skeletal maturity (Risser 4-5), assessed up to 18 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in